Annual report pursuant to Section 13 and 15(d)

Shareholders Equity

v3.6.0.2
Shareholders Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-In Capital
Treasury Stock
Other Comprehensive Income / Loss
Retained Earnings / Accumulated Deficit
Total
Balance at Dec. 31, 2014 $ 14 $ 129,130 $ (10,039) $ (66) $ (95,659) $ 23,380
Balance (in shares) at Dec. 31, 2014 13,120,386         13,120,386
Stock-based compensation for issuance of common stock warrants for third-party services   65       $ 65
Stock-based compensation   15,082       15,082
Stock-based compensation (in shares) 214,394          
Issuance of common stock for:            
Stock issued for product line expansion $ 1,198 1,198       1,198
Stock issued for product line expansion (in shares) 150,000          
Stock issued for MusclePharm apparel rights acquisition   1,394       1,394
Stock issued for MusclePharm apparel rights acquisition (in shares) 170,000          
Stock issued for attempted financing agreement $ 325 325       325
Stock issued for attempted financing agreement (in shares) 50,000          
Stock issued for non-employee consulting and endorsement agreement $ 320 320       320
Stock issued for non-employee consulting and endorsement agreement (in shares) 55,189          
Stock-based compensation for issuance of common stock to a related party for guaranty of debt   80       80
Stock-based compensation for issuance of common stock to a related party for guaranty of debt (in shares) 28,571          
Beneficial conversion feature related to convertible note   52       52
Issuance of warrants for legal settlement           0
Change in foreign currency translation adjustment       (106)   (106)
Net loss         (51,858) (51,858)
Balance at Dec. 31, 2015 $ 14 147,646 (10,039) (172) (147,517) $ (10,068)
Balance (in shares) at Dec. 31, 2015 13,788,540         13,788,540
Stock-based compensation for issuance of common stock warrants for third-party services   6       $ 6
Stock-based compensation   1,708       1,708
Stock-based compensation (in shares) 572,154          
Issuance of common stock for:            
Stock issued for MusclePharm apparel rights acquisition           0
Beneficial conversion feature related to convertible note   601       601
Stock-based compensation for accelerated vesting of restricted stock awards to a terminated executive   3,900       3,900
Stock-based compensation for accelerated vesting of restricted stock awards to terminated employees as part of restructuring   288       288
Stock-based compensation for issuance of stock options to an executive and a director   153       153
Issuance of shares of common stock related to sale of subsidiary $ 640 640       640
Issuance of shares of common stock related to sale of subsidiary (in shares) 200,000          
Issuance of warrants for legal settlement   1,815       1,815
Cancellation of executive restricted stock $ (456) (456)       (456)
Cancellation of executive restricted stock (in shares) (449,085)          
Change in foreign currency translation adjustment       10   10
Net loss         (3,477) (3,477)
Balance at Dec. 31, 2016 $ 14 $ 156,301 $ (10,039) $ (162) $ (150,994) $ (4,880)
Balance (in shares) at Dec. 31, 2016 14,411,609         14,111,609